ANCA-associated vasculitis historically required prolonged high-dose steroids. New targeted therapies include:
- Avacopan (Tavneos®) – C5a receptor inhibition
- Rituximab-based regimens for B-cell–mediated disease
These approaches reduce steroid toxicity while maintaining disease control.